Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00190658 · ClinicalTrials.gov registry record · Phase 3
Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 75
- Enrollment target
NCT00190658 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 75 participants.
The verdict
NCT00190658, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 75 participants
- Enrollment target
Study Summary
This clinical trial will compare the mean first year height velocity of somatropin-treated prepubertal patients with SHOX deficiency with the height velocity of a control group of untreated prepubertal patients with SHOX deficiency. Both groups will be compared to a somatropin-treated group of girls with Turner syndrome. After the second year patients in the control group have the option to receive treatment as well. All patients will optionally be treated until they achieved adult height.
Interventions
- DRUG Somatropin (rDNA origin) for injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2000-02 |
| Est. Completion | 2010-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00190658
The ClinicalTrials.gov registry entry for NCT00190658 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Somatropin (rDNA origin) for injection is the first listed.
NCT00190658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00190658 about?
NCT00190658 is a clinical study titled "Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome". This clinical trial will compare the mean first year height velocity of somatropin-treated prepubertal patients with SHOX deficiency with the height velocity of a control group of untreated prepubertal patients with SHOX deficiency. Both groups will be compared to a somatropin-treated group of girls...
What is the current status of trial NCT00190658?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 75 participants. The study started on 2000-02. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00190658?
The interventions under investigation include: Somatropin (rDNA origin) for injection (DRUG).
Who is sponsoring clinical trial NCT00190658?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.